BioSpace News Archive

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will report fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.

Prothena Corporation plc announced that members of its senior management team will participate in the following upcoming investor conferences.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

IN8bio, Inc. a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced the presentation of new preclinical data for its non-signaling gamma-delta T cell based Chimeric Antigen Receptor T cell platform, INB-300.

RAPT Therapeutics, Inc. announced the acceptance of three late-breaking abstracts for poster presentation, including a poster presentation for tivumecirnon, its lead oncology drug candidate, highlighting phase 2 clinical data in head and neck squamous cell carcinoma, at the American Association for Cancer Research Annual Meeting which will take place April 5-10, 2024 in San Diego, CA.

ALX Oncology Holdings Inc. announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research Annual Meeting, which will be held in San Diego from April 5-10, 2024.

C4 Therapeutics, Inc. announced the acceptance of two preclinical poster presentations at the American Association for Cancer Research Annual Meeting 2024 taking place April 5-10, 2024 in San Diego, California.

Nurix Therapeutics, Inc. announced that Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix, is invited as a featured speaker in two sessions at the American Association for Cancer Research 2024 Annual Meeting, which will be held from April 5-10, 2024, in San Diego, CA.

Merus N.V. announced the publication of an abstract highlighting the preclinical evaluation of the bispecific antibody zenocutuzumab for poster presentation at the American Association for Cancer Research Annual Meeting 2024 taking place in San Diego, CA April 5-10, 2024.